Phase 2 Trial Shows mRNA Vaccine Plus Pembrolizumab Lowers Melanoma Recurrence Risk by 44 Percent

The trial measured recurrence-free survival as the primary endpoint using Kaplan-Meier estimates and Cox modeling. Patients received up to nine doses of the vaccine encoding up to 34 neoantigens identified from tumor sequencing. Absolute recurrence rates were 22 percent in the combination arm versus 40 percent in the control arm, yielding a hazard ratio of 0.56.

Context from prior observational data and smaller single-arm studies indicated neoantigen vaccines could elicit T-cell responses, yet this is the first randomized signal in melanoma. The result aligns with patterns seen in checkpoint-inhibitor combinations but remains limited by modest sample size and short follow-up that does not yet address overall survival.

Next steps require the ongoing phase 3 trial to confirm durability beyond two years and to test whether similar platforms can extend to glioblastoma and pancreatic cancers, where neoantigen burden and immunosuppressive microenvironments differ substantially.

Regulatory filing is unlikely before phase 3 readout; any accelerated approval would hinge on mature recurrence-free survival data and acceptable safety.